9,260 reports of this reaction
6.6% of all PEGINTERFERON ALFA 2A reports
#1 most reported adverse reaction
FATIGUE is the #1 most commonly reported adverse reaction for PEGINTERFERON ALFA 2A, manufactured by pharmaand GmbH. There are 9,260 FDA adverse event reports linking PEGINTERFERON ALFA 2A to FATIGUE. This represents approximately 6.6% of all 141,362 adverse event reports for this drug.
PEGINTERFERON ALFA 2A has an overall safety score of 85 out of 100. Patients taking PEGINTERFERON ALFA 2A who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among PEGINTERFERON ALFA 2A users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for PEGINTERFERON ALFA 2A:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 9,260 FDA reports for PEGINTERFERON ALFA 2A. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 6.6% of all adverse event reports for PEGINTERFERON ALFA 2A, making it one of the most commonly reported side effect.
If you experience fatigue while taking PEGINTERFERON ALFA 2A, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.